search

Myriad Genetics Inc (MYGN)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset
Sep 18, 2026

Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset

Myriad Genetics (MYGN) has seen its modelled fair value estimate cut by nearly 46% to US$3.37 after a reset in analyst price targets and reduced FY26 guidance. This shift reflects increased caution regarding execution risk, profitability, and payer friction in certain testing volumes. Analysts have issued mixed ratings, with some maintaining neutral positions while others, like Piper Sandler, downgraded the stock due to profitability concerns.
Company relevance
100.00%
Company sentiment
Bearish
Overall sentiment
Somewhat-Bearish
Myriad Genetics (NASDAQ: MYGN) Confirms 2026 Financial Outlook Amid Executive Commercial Leadership Shift
Sep 17, 2026

Myriad Genetics (NASDAQ: MYGN) Confirms 2026 Financial Outlook Amid Executive Commercial Leadership Shift

Myriad Genetics has appointed Vishal Sikri as executive vice president, commercial, effective September 16, 2026, succeeding Brian Donnelly. Donnelly will remain a non-executive employee until September 21, 2026, to ensure a smooth transition. The company also reaffirmed its full-year 2026 financial guidance.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish